Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Editorial Office

DOI: https://doi.org/10.21037/tp-2024-02

2024-09-02

Translational Pediatrics

Abstract:Editorial Office Translational Pediatrics Submitted Jul 15, 2024. Accepted for publication Jul 25, 2024. Published online Aug 28, 2024. doi: 10.21037/tp-2024-02 Erratum to: Transl Pediatr 2023;12:1926-30. The article (1) entitled "Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients" ( Transl Pediatr 2023;12:1926-30. doi: 10.21037/tp-23-391) unfortunately contained some mistakes in the main text on page 1929. In paragraph 14, the "event-free-survival" should be "overall survival". The OS should be EFS. The data "91%±4.4% (≤2006) versus 88%±4.3% (>2006)" should be "89%±5.1% (≤2006) versus 87%±4.6% (>2006)". The corrected content is presented as below: Survival analyses revealed that there were no significant differences in overall survival after the reassignment being 89%±5.1% (≤2006) versus 94%±3.2% (>2006). The similar trend was observed for EFS showing 89%±5.1% (≤2006) versus 87%±4.6% (>2006). The small increase in OS observed in the group of patients treated >2006 could be due to the better response of a small subset of patients that relapse. The authors apologize for these errors and state that these errors do not change the scientific conclusions of the article in any way. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

pediatrics

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:

Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

Erratum: Aldenhoven M, van den Broek BTA, Wynn RF, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236-2242

Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Correction to "Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes"

Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126

Erratum: Veenstra RG, Flynn R, Kreymborg K, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015;125(21):3335-3346

Erratum: Parry EM, Alder JK, Qi X, Chen JJ-L, Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607-5611

Erratum: Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-721

Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946

Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"

Erratum: Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046

Erratum: Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343-2347

Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum

Erratum: Development of Auer bodies from giant inclusions associated with rough endoplasmic reticulum in acute promyelocytic leukemia

Erratum: Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report: erratum

Erratum: Flanagan JM, Sheehan V, Linder H, et al. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood. 2013;121(16):3237-3245

Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy